Efficacy and safety of setmelanotide, an mc4r agonist, in individuals with severe obesity due to lepr or pomc deficiency: single-arm, open-label, multicentre, phase 3 trials
Dehydration, often due to gastrointestinal effects of Mounjaro, can lead to concentrated, stronger-smelling urine
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Brody, T
Topical glutathione: topical formulations are typically 1-2 % glutathione
L-methylfolate: Targeted therapy begins
